Clinical, Laboratory, and Ultrasound Related Diagnoses of Thyroid Disorders: Using a Family Medicine Center Data to Assess Thyroiditis and Thyroid Nodules in the Eastern Province of Saudi Arabia

Malak A. Al-Shammari1, Moataza M. Abdel Wahab1, Nouf A. AlShamlan1, Reem S. AlOmar1, Abdullatif K. Althunyan1, Layla M. Alghamdi1, Adam Fahad Aldhawyan1, Naheel A. AlAmer1, Sara A. Elmaki2, and Omran Al Dandan2

Abstract

Introduction/Objectives: The prevalence of thyroid disorders is high in Saudi Arabia. Among the disorders, goiter and thyroiditis are the most common and have unique ultrasound (US) features, underscoring the need for US screening for thyroid pathologies. This study aimed to determine the prevalence of thyroiditis and thyroid nodules in patients attending the Family and Community Medicine Center of Imam Abdulrahman Bin Faisal University. Methods: This registry-based cross-sectional study analyzed laboratory and US data from 240 patients who attended the Family and Community Medicine Center of Imam Abdulrahman Bin Faisal University from January 2020 to December 2021. Abnormalities of the thyroid gland were categorized according to laboratory and US data. Associations between different types of thyroid pathology and clinical and laboratory findings were assessed using appropriate statistical methods. Results: The majority of participants were Saudi women. The prevalence of thyroiditis in the study population was 43%. Approximately 25% of these patients had more than 1 nodule, and fine-needle aspiration biopsy showed that most nodules were benign. Most nodules were found in clinically euthyroid patients. Thyroiditis might be associated with abnormal thyroid function. Conclusions: Thyroiditis and thyroid nodules were common in our cohort. Vitamin D deficiency, other autoimmune diseases, and a family history of thyroid disorders were associated with thyroiditis and thyroid nodules. US is useful for identifying the type of thyroid disease.

Keywords

goiter, thyroid nodule, thyroid, thyroiditis, ultrasound

Dates received: 10 March 2022; revised: 31 March 2022; accepted: 2 April 2022.

Introduction

Thyroid diseases are highly prevalent worldwide and are a major health problem.1 Thyroid diseases are the most common endocrine disorders in Saudi Arabia and other Arab countries.2

Goiter is the most common thyroid disease. Clinical manifestations and thyroid hormone levels vary depending on disease etiology and the presence of cancerous tissues, which are found in up to 15% of patients with goiter. This high prevalence underscores the need to screen goiter patients for thyroid cancer.3,4

Thyroiditis comprises a diverse group of disorders and is classified as painless or painful. Thyroid hormone levels range from hyperthyroidism to hypothyroidism spectrum during the disease progress until it eventually normalizes in most cases.5 Hashimoto’s thyroiditis (HT) is the most common form of painless thyroiditis. The most frequent cause

1Department of Family and Community Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
2Department of Radiology, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Corresponding Author:
Malak A. Al-Shammari, Department of Family and Community Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Saudi Arabia.
Email: moalshammari@iau.edu.sa
of hypothyroidism in the United States is HT.6 Thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb) are sensitive serological markers of HT. Moreover, there is a significant correlation between TPOAb levels and the ultrasound (US) features of HT.7,8

A palpable thyroid nodule is a common presentation affecting around 7% of people and is associated with cancers in 20% of cases.9,10 US is an invaluable tool for predicting malignant thyroid nodules.11 Therefore, thyroid US is an important tool for evaluating patients with varying thyroid pathologies.12 Nevertheless, few studies have evaluated the diagnostic utility of US for thyroid disorders in primary healthcare settings.

Considering the high incidence of thyroid disorders in Saudi Arabia, it becomes imperative to explore this matter. The aim of conducting such a registry-based study is to gain true access to the frequency of thyroid disorders among Saudis and non-Saudis living in the area and its associated data. Hence, the objective of this study is to determine the frequency of thyroiditis and thyroid nodules detected by ultrasound scans among our study population of patients attending the Family and Community Medicine Center (FAMCO) in Imam Abdulrahman Bin Faisal University (IAU) and its associated clinical and laboratory data.

**Methods**

This registry-based cross-sectional study analyzed laboratory and thyroid US data from all patients who attended the Family and Community Medicine Center of Imam Abdulrahman Bin Faisal University in the period January 2020 to December 2021.

**Family and Community Medicine Center**

The Primary Health Care Center of Imam Abdulrahman Bin Faisal University, located in Dammam City, in the Eastern province of Saudi Arabia, has a fully functioning radiological department that serves university faculty, staff, and their family members, as well as local residents.

Laboratory and imaging data were retrieved from medical records using Quadrimed_2019_prog_Stes medicals software.

**Study Population**

A total of 240 adult patients who underwent US examinations between January 2020 and December 2021 were enrolled. These patients were referred to the radiology department of our center and, if necessary, to the pathology, endocrinology, and surgical departments of King Fahd Hospital of Imam Abdulrahman Bin Faisal University.

**Data Collection**

Demographic data, medical history, thyroid US features, and the results of thyroid function tests and fine-needle aspiration biopsy (FNAB) were obtained from medical records.

**Data Management and Analysis**

Thyroiditis was considered according to the heterogenous pattern of the thyroid gland on US. The patients with free triiodothyronine (FT3) levels of 1.71 to 3.71 pg/ml, free thyroxin (FT4) levels of 0.70 to 1.48 ng/dl, and thyroid-stimulating hormone (TSH) levels of 0.35 to 4.94 µIU/ml were considered euthyroid. Hypothyroidism was considered FT3 or FT4 levels below this range or TSH levels above this range, whereas hyperthyroidism was considered FT3 or FT4 levels above this range or TSH levels below this range. The presence of vitamin D deficiency (plasma 25-hydroxy vitamin D level of less than 12 ng/ml) and comorbidities (autoimmune, hematologic, or psychiatric diseases) were assessed within 12 months before or after the thyroid US. Patients with neck swelling, hoarseness, compression of the esophagus and/or trachea, or dysphagia were subjected to US examinations. Patient concern is upon patient request or a known case of thyroid pathology diagnosed in another center and followed up.

The data were analyzed using SPSS version 21.0. The significance level was set at \( P < .05 \). Categorical data were presented as numbers and percentages. Associations between thyroiditis or thyroid nodules and potential risk factors were assessed using the chi-square test and Z-test for proportions in cases of multiple responses. The odds ratio (OR) and 95% confidence interval (CI) were calculated for significant associations.

Two multiple logistic regression models were used to identify demographic and clinical characteristics independently associated with thyroiditis and thyroid nodules. The enter method was used, and adjusted ORs and 95% CIs were measured.

The accuracy of the clinical diagnosis of goiter by family physicians was evaluated using US as the gold standard. The following parameters were calculated based on the number of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN): sensitivity (TP/TP + FN), specificity (TN/TN + FP), positive predictive value (PPV; TP/TP + FP), negative predictive value (NPV; TN/TN + FN).

**Results**

A total of 240 patients were enrolled in the study. The median age was 37 (10-92) years, and 57.5% of the cohort were aged 20 to 40 years. The majority (85.4%) of the
patients were women, 6% were pregnant, and 15.1% had given birth or had a miscarriage within 12 months before thyroid US examinations. At presentation, 53.8%, 29.2%, and 15.0% of the cohort were euthyroid, hypothyroid, and hyperthyroid, respectively. Our population was referred for US examination because of the presence of symptoms (38.8%), abnormal levels in thyroid function tests (36.3%), and patient request (25%).

The analysis of demographic and laboratory data according to the presence or absence of US features of thyroiditis is shown in Table 1. Almost 43% of the patients had thyroiditis based on US features, and these features were more common in women (OR, 2.46; 95% CI, 1.10-5.53). There was no significant association between thyroiditis and pregnancy or childbirth within 12 months before US examinations. Of those with thyroiditis, 80.6% were Saudi nationals. The risk of thyroiditis was higher in hypothyroid patients (OR, 5.14; 95% CI, 2.74-9.64) and hyperthyroid patients (OR, 4.02; 95% CI, 1.84-8.78) than in euthyroid individuals. The size of the thyroid gland was normal in 66% of the patients with thyroiditis. The risk of thyroiditis was higher among those with 1 enlarged lobe (OR, 4.06; 95% CI, 1.59-10.37) and those with diffuse enlargement of the gland (OR, 4.22; 95% CI, 1.75-10.16). With regards to laboratory results, the risk of thyroiditis was higher in hypothyroid patients (OR, 4.28; 95% CI, 1.14-16.06) and lower in hypothyroid patients (OR, 0.64; 95% CI, 0.18-2.20) according to FT3 levels. Furthermore, the risk of thyroiditis was higher in patients with low TSH (OR, 5.52; 95% CI, 2.57-11.86) and high TSH (OR, 6.69; 95% CI, 3.08-14.52) than in patients with normal TSH levels (Table 1).

Among patients with US features of thyroiditis, 17.5% had 1 nodule, and 23.3% had more than 1 nodule. FNAB was performed in 11 patients with thyroid nodules; of these, 1 case was suspicious, 9 cases were benign, and 1 patient had unsatisfactory results (Table 1).

Goiter was detected clinically in 41 patients (17.2%) and ultrasonographically in 25 patients (10.4%). The accuracy, sensitivity, specificity, NPV, and PPV of the clinical diagnosis of goiter using US as the gold standard were 90.3%, 87.5%, 90.7%, 98.5%, and 51.2%, respectively.

Nodules were detected in 104 (43.3%) patients; of these, almost 50% had 1 nodule, and the remaining patients had multiple nodules. Nodules were located unilaterally in 96% of cases and bilaterally in 3.9% of cases. The nodule size was >1 cm in 73 (71%) of patients. The nodules were solid, cystic, or mixed in 56.4%, 17.8%, and 24.8% of cases. The nodules had a heterogeneous pattern in 66.3% of patients. The US pattern was hypoechoic, isoechoic, hyperechoic, mixed, or anechoic in 23.8%, 14.0%, 10.0%, 49.5%, and 3.0% of cases.

The analysis of clinical data according to the presence or absence of US features of thyroiditis is shown in Table 2. The risk of thyroiditis was higher among participants with vitamin D deficiency (OR, 5.75; 95% CI 2.10-15.72) and those with comorbidities (autoimmune diseases and iron deficiency anemia) diagnosed within 12 months before or after the diagnosis of thyroiditis (OR, 3.07; 95% CI, 1.63-5.78). Moreover, a family history of thyroid diseases significantly increased the risk of thyroiditis (OR, 4.93; 95% CI, 2.83-8.59).

The analysis of demographic, laboratory, and imaging data according to the presence or absence of thyroid nodules is shown in Table 3. The number of nodules was higher in older patients. The risk of developing nodules was lower among men (OR, 0.40; 95% CI, 0.17-0.89). In addition, 67.3% of patients with nodules were euthyroid at presentation. The risk of nodules was lower in hypothyroidism (OR, 0.38; 95% CI, 0.20-0.71) and hyperthyroidism (OR, 0.37; 95% CI, 0.16-0.81) than in euthyroidism before adjusting for potential confounders. Goiter was not diagnosed clinically in 74.8% of patients with nodules. However, the risk of nodules was higher in the group with goiter (OR, 2.72; 95% CI, 1.35-5.46). The majority of patients with nodules were euthyroid based on FT3, FT4, or TSH levels.

Four Saudi women had malignant thyroid nodules based on FNAB results (2 aged 20-39 years and 2 aged 40-59 years); of these, 2 patients were euthyroid, 1 was hypothyroid, and 1 case was unknown. Four patients had a normal-sized thyroid gland on US, and 2 were clinically diagnosed with goiter. The thyroid pattern was homogenous in 3 cases and heterogeneous in 1 case. One patient had no nodules, 2 had 1 nodule, and 1 had 3 nodules larger than 1 cm. The nodule was solid in 2 cases and mixed (solid and cystic) in 1 case. Pathological lymph nodes were present in 1 patient. An increase in vascularity in 1 patient and all were negative for calcification.

The analysis of vitamin D status and comorbidities according to the presence or absence of thyroid nodules is shown in Table 4. Autoimmune diseases, diabetes mellitus type 2, hypertension, iron deficiency anemia, vitamin D deficiency, and a family history of thyroid diseases were associated with the presence of thyroid nodules.

The results of logistic regression analysis suggest that the risk of thyroiditis was higher in patients with an enlarged thyroid gland, autoimmune diseases, vitamin D deficiency, and a family history of thyroid disorders. The risk of developing thyroid nodules was higher in patients with iron deficiency anemia, autoimmune diseases, hypertension, vitamin D deficiency, and a family history of thyroid disorders. The risk factors for developing thyroiditis and thyroid nodules are presented in Table 5.

**Discussion**

Although different types of thyroid disease are being diagnosed and treated, benign thyroid diseases are more prevalent in Saudi Arabia and other countries.13,14
**Table 1.** Association Between Ultrasonographic (US) Features of Thyroiditis and Personal and Laboratory Characteristics of Patients in the Family Medicine Center, Saudi Arabia (January 2020-December 2021) (N = 239).

| US features of thyroiditis | % from positive thyroiditis (n = 103) | No. | %  | Yes. | %  | P    |
|----------------------------|---------------------------------------|-----|----|------|----|------|
| **Age (years)**            |                                       |     |    |      |    |      |
| Less than 20               | 3.9                                   | 7   | 63.6 | 4   | 36.4 |      |
| 20 less than 40            | 53.4                                  | 82  | 59.9 | 55  | 40.1 | .629 |
| 40 less than 60            | 35.9                                  | 39  | 51.3 | 37  | 48.7 |      |
| 60+                       | 6.8                                   | 8   | 53.3 | 7   | 46.7 |      |
| **Sex**                    |                                       |     |    |      |    |      |
| Male                      | 8.7                                   | 26  | 74.3 | 9   | 25.7 | .025 |
| Female                    | 91.3                                  | 110 | 53.9 | 94  | 46.1 |      |
| **Nationality**            |                                       |     |    |      |    |      |
| Saudi                     | 80.6                                  | 100 | 54.6 | 83  | 45.4 | .202 |
| Non-Saudi                 | 19.4                                  | 36  | 64.3 | 20  | 35.7 |      |
| **Known thyroid status at presentation** |                               |     |    |      |    |      |
| Euthyroid                 | 34.0                                  | 94  | 72.9 | 35  | 27.1 |      |
| Hypothyroid               | 44.7                                  | 24  | 34.3 | 46  | 65.7 | .001 |
| Hyperthyroid              | 20.3                                  | 14  | 40.0 | 21  | 60.0 |      |
| Unknown                   | 1.0                                   | 4   | 80.0 | 1   | 20.0 |      |
| **TPOAb**                 |                                       |     |    |      |    |      |
| Negative                  | 9.8                                   | 40  | 80.0 | 10  | 20.0 |      |
| Positive                  | 52.9                                  | 17  | 23.9 | 54  | 76.1 | .001 |
| Not done                  | 37.3                                  | 78  | 67.2 | 38  | 32.8 |      |
| **TgAb**                  |                                       |     |    |      |    |      |
| Negative                  | 9.7                                   | 28  | 73.7 | 10  | 26.3 |      |
| Positive                  | 52.4                                  | 24  | 30.8 | 54  | 69.2 | .001 |
| Not done                  | 37.9                                  | 83  | 68.0 | 39  | 32.0 |      |
| **Size of the thyroid gland** |                                   |     |    |      |    |      |
| Normal                    | 66.0                                  | 121 | 64.0 | 68  | 36.0 |      |
| 1 lobe enlarged           | 15.5                                  | 7   | 30.5 | 16  | 69.5 | .001 |
| Enlarged globally         | 18.4                                  | 8   | 29.6 | 19  | 70.4 |      |
| **Goiter (by US)**        |                                       |     |    |      |    |      |
| No goiter                 | 84.5                                  | 127 | 59.3 | 87  | 40.7 |      |
| Diffuse                   | 8.7                                   | 3   | 25.0 | 9   | 75.0 | .047 |
| Multinodular              | 6.8                                   | 6   | 46.2 | 7   | 53.8 |      |
| **Clinical goiter**       |                                       |     |    |      |    |      |
| No goiter                 | 78.4                                  | 117 | 59.4 | 80  | 40.6 | .125 |
| Clinical goiter           | 21.6                                  | 19  | 46.3 | 22  | 53.7 |      |
| **Nodule**                |                                       |     |    |      |    |      |
| No                        | 59.2                                  | 74  | 54.8 | 61  | 45.2 |      |
| 1 nodule                  | 17.5                                  | 34  | 65.4 | 18  | 34.6 | .375 |
| Multiple nodules          | 23.3                                  | 28  | 53.8 | 24  | 46.2 |      |
| **FT3**                   |                                       |     |    |      |    |      |
| Euthyroid                 | 85.3                                  | 104 | 56.2 | 81  | 43.8 |      |
| Hypothyroid               | 4.2                                   | 8   | 66.7 | 4   | 33.3 | .047 |
| Hyperthyroid              | 10.5                                  | 3   | 23.1 | 10  | 76.9 |      |
| **FT4**                   |                                       |     |    |      |    |      |
| Euthyroid                 | 79.2                                  | 109 | 57.7 | 80  | 42.3 |      |
| Hypothyroid               | 5.0                                   | 1   | 16.7 | 5   | 83.3 | .031 |
| Hyperthyroid              | 15.8                                  | 10  | 38.5 | 16  | 61.5 |      |
| **TSH**                   |                                       |     |    |      |    |      |
| Normal TSH                | 43.6                                  | 108 | 71.1 | 44  | 28.9 |      |
| Low TSH                   | 26.7                                  | 12  | 30.8 | 27  | 69.2 | .001 |
| High TSH                  | 29.7                                  | 11  | 26.8 | 30  | 73.2 |      |
| **FNA**                   |                                       |     |    |      |    |      |
| Not done                  | 89.3                                  | 116 | 55.8 | 92  | 44.2 | .447 |
| Done                      | 10.7                                  | 20  | 64.5 | 11  | 35.5 |      |

(continued)
Table 2. Association Between Ultrasonographic Features of Thyroiditis and Clinical Characteristics of Patients in the Family Medicine Center, Saudi Arabia (January 2020-December 2021) (N = 239).

| US features of thyroiditis | Vitamin D deficiency | Comorbidity diagnosed within 12 months of US scan | Type of comorbidity<sup>a,b,c</sup> | Family history of any thyroid disorder | Clinical background<sup>d</sup> | Outcome |
|---------------------------|----------------------|-----------------------------------------------|------------------------------------|---------------------------------|----------------------|---------|
|                           | No (n=136)           | Yes (n=103)                                   |                                    |                                 |                      |         |
|                           | No. %                | No. %                                         | No. %                              | No. %                           | No. %                | P       |
| FNA results               |                      |                                               |                                    |                                 |                      |         |
| Unsatisfactory            | 9.1                  | 5 83.3                                        | 1 16.7                             | .445                            |                      |         |
| Benign                    | 81.8                 | 12 57.1                                       | 9 42.9                             | .001                            |                      |         |
| Suspicious or Malignant   | 9.1                  | 3 75.0                                        | 1 25.0                             | .445                            |                      |         |

Abbreviations: FNA: Fine needle aspiration; FT3: free triiodothyronine; FT4: free Thyroxin; TgAb: antithyroglobulin antibodies; TPOAb: thyroid peroxidase antibodies; TSH: thyroid stimulating hormone.

US features of thyroiditis were not recorded in 1 file.

% from positive thyroiditis (n = 103)

| FNA results | No. | %   | No. | %   | P     |
|-------------|-----|-----|-----|-----|-------|
| Unsatisfactory | 9.1 | 5   | 1   | 16.7 | .445  |
| Benign       | 81.8| 12  | 9   | 42.9 | .001  |
| Suspicious or Malignant | 9.1 | 3   | 1   | 25.0 | .445  |

<sup>a</sup>1 patient may have more than 1 answer.

<sup>b</sup>% calculated from positive comorbidity.

<sup>c</sup>Autoimmune: varied cases of systemic lupus erythematosis, rheumatoid arthritis, Type 1 diabetes mellitus, Graves’ disease, Multiple sclerosis, Vitiligo. Psychiatric disorders: anxiety, depression, 1 patient with schizophrenia. Others: malignancy (breast, nasopharynx, pituitary), neurological (trigeminal neuralgia, migraine, disc prolapse), dermatological (acne vulgaris, urticaria), irritable bowel syndrome.

<sup>d</sup>Others: Malignancy (leukemia, breast), Osteoporosis, Migraine, Fatty liver.
### Table 3. Association Between Thyroid Nodule(s) and Personal and Laboratory Characteristics of Patients in the Family Medicine Center, Saudi Arabia (January 2020-December 2021) (N=240).

|                           | Presence of nodule(s) |       |       |
|---------------------------|-----------------------|-------|-------|
|                           | No                    | I or multiple node(s) |       |
|                           | No. | %          | No. | %  | P    |
|                           |     |            |     |     |      |
| **Age**                   |     |            |     |     |      |
| Less than 20              |     |            |     |     |      |
| 20 less than 40           | 11  | 100.0      | 48  | 34.8|      |
| 40 less than 60           | 90  | 65.2       | 43  | 56.6| .0001|
| 60+                       | 2   | 13.3       | 13  | 86.7|      |
| **Sex**                   |     |            |     |     |      |
| Male                      | 26  | 74.3       | 9   | 25.7| .023 |
| Female                    | 110 | 53.7       | 95  | 46.3|      |
| **Nationality**           |     |            |     |     |      |
| Saudi                     | 107 | 58.2       | 77  | 41.8| .4   |
| Non-Saudi                 | 29  | 51.8       | 27  | 48.2|      |
| **Thyroid status at presentation** |     |            |     |     |      |
| Euthyroid                 | 59  | 45.7       | 70  | 54.3|      |
| Hypothyroid               | 48  | 68.6       | 22  | 31.4| .003 |
| Hyperthyroid              | 25  | 69.4       | 11  | 30.6|      |
| Unknown                   | 4   | 80.0       | 1   | 20.0|      |
| **Patterns of thyroid**   |     |            |     |     |      |
| Homogeneous               | 74  | 54.4       | 62  | 45.6| .457 |
| Heterogenous              | 61  | 59.2       | 42  | 40.8|      |
| **Clinical goiter**       |     |            |     |     |      |
| No goiter                 | 121 | 61.1       | 77  | 38.9| .004 |
| Clinical goiter           | 15  | 36.6       | 26  | 63.4|      |
| **Lymph nodes**           |     |            |     |     |      |
| Negative                  | 115 | 56.1       | 90  | 43.9|      |
| Reactive                  | 16  | 57.1       | 12  | 42.9| .726 |
| Pathological              | 1   | 33.3       | 2   | 66.7|      |
| **Vascularity**           |     |            |     |     |      |
| Negative                  | 133 | 64.6       | 73  | 35.4| .0001|
| Positive                  | 3   | 8.8        | 31  | 91.2|      |
| **Calcifications**        |     |            |     |     |      |
| Negative                  | 132 | 60.0       | 88  | 40.0| .0001|
| Positive                  | 1   | 5.9        | 16  | 94.1|      |
| **FT3**                   |     |            |     |     |      |
| Euthyroid                 | 101 | 54.3       | 85  | 45.7|      |
| Hypothyroid               | 4   | 33.3       | 8   | 66.7| .09  |
| Hyperthyroid              | 10  | 76.9       | 3   | 23.1|      |
| **FT4**                   |     |            |     |     |      |
| Euthyroid                 | 103 | 54.2       | 87  | 45.8|      |
| Hypothyroid               | 4   | 66.7       | 2   | 33.3| .797 |
| Hyperthyroid              | 15  | 57.7       | 11  | 42.3|      |
| **TSH**                   |     |            |     |     |      |
| Normal TSH                | 76  | 50.0       | 76  | 50.0|      |
| Low TSH                   | 24  | 60.0       | 16  | 40.0| .025 |
| High TSH                  | 30  | 73.2       | 11  | 26.8|      |

Abbreviations: FT3: free triiodothyronine; FT4: free Thyroxin; TSH: thyroid stimulating hormone.
Thyroid diseases are managed medically and surgically. Thyroiditis was highly prevalent among female Saudi nationals who tested positive for autoantibodies in our study. These are some of the known associations of autoimmune diseases in general and autoimmune thyroid diseases specifically.15 Most of these conditions are benign and self-limiting and require treatment only when associated with hypo- or hyperthyroidism.15,16 Association between US echogenicity of the thyroid and thyroid functions has rarely been reported before.17 Patients with thyroid dysfunctions in our study were more likely to have US features of thyroiditis, consistent with a previous study.18 Using heterogeneity of the thyroid gland pattern on the scan as an indicator of thyroiditis, an inflammatory process of the thyroid gland, has been reported in other international studies with other markers such as US echogenicity and Doppler US have been used to differentiate acute from subacute thyroiditis.17,19 These techniques are useful to detect thyroid pathologies but may vary across regions according to the level of experience of radiologists and the methods adopted for analyzing and reporting US results. Our radiologist was an experienced radiology consultant certified in the United Kingdom with more than 10 years of experience in thyroid US.

| Table 4. Association Between Thyroid Nodule(s) and Clinical Characteristics of Patients in the Family Medicine Center, Saudi Arabia (January 2020-December 2021) (N=240). |
|---|
| **Presence of nodule(s)** |  |
| | No (n = 136) | 1 or multiple nodule(s) (n = 104) |
| | No. | % | No. | % |
| **Vitamin D deficiency** |  |  |  |  |
| No | 22 | 16.2 | 11 | 10.6 |
| Yes | 74 | 54.4 | 73 | 70.2 | .045 |
| Not done | 40 | 29.4 | 20 | 19.2 |
| **Comorbidity diagnosed within 12 months of US scan** |  |  |  |  |
| No | 67 | 49.3 | 84 | 80.8 | .0001 |
| Yes | 69 | 50.7 | 20 | 19.2 |
| **Type of comorbidity** |  |  |  |  |
| Autoimmune | 7 | 10.1 | 12 | 60.0 | .0001 |
| Iron deficiency | 29 | 42.0 | 13 | 65.0 | .069 |
| **Infertility** | 15 | 21.7 | 4 | 20.0 | .867 |
| Psychiatric | 13 | 18.8 | 0 | 0.0 | .036 |
| Other | 24 | 34.8 | 2 | 10.0 | .0001 |
| **Family history of any thyroid disorder** |  |  |  |  |
| No | 89 | 65.4 | 50 | 48.1 |
| Yes | 47 | 34.6 | 54 | 51.9 | .007 |
| **Clinical background** |  |  |  |  |
| DM Type II | 12 | 8.8 | 21 | 20.2 | .011 |
| Hypertension | 13 | 9.6 | 27 | 26.0 | .0001 |
| Dyslipidemia | 18 | 13.2 | 23 | 22.1 | .070 |
| Iron deficiency | 8 | 5.9 | 44 | 42.3 | .0001 |
| **Other** | 24 | 34.8 | 2 | 10.0 | .0001 |
| **Outcome** |  |  |  |  |
| Follow up | 132 | 97.1 | 87 | 83.7 | .001 |
| Total resection | 3 | 2.2 | 9 | 8.7 |  |
| Partial resection | 1 | 0.7 | 8 | 7.7 |

*a1 patient may have more than 1 answer.

b% calculated from positive comorbidity.

cAutoimmune: systemic lupus erythematosatis, rheumatoid arthritis, Type 1 diabetes mellitus, Graves’ disease, Multiple sclerosis, Vitiligo. Psychiatric disorders: anxiety, depression, 1 patient with schizophrenia. Others: malignancy (breast, nasopharynx, pituitary), neurological (trigeminal neuralgia, migraine, disc prolapse), dermatological (acne vulgaris, urticaria), irritable bowel syndrome.

dOthers: Malignancy (leukemia, breast), Osteoporosis, Migraine, Fatty liver.
The risk of thyroiditis in our study was higher among patients with vitamin D deficiency. There is a correlation between vitamin D deficiency and autoimmune thyroiditis, especially HT, and other autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis, suggesting that vitamin D plays a major role in immune regulation. Moreover, vitamin D deficiency is closely related to higher levels of thyroid peroxidase antibodies, especially in HT. Autoimmune thyroid diseases are characterized by enlargement of the thyroid gland, consistent with our findings.

The prevalence of goiter is high worldwide but has decreased significantly after implementing salt iodization programs. The high accuracy of the clinical diagnosis of goiter by primary care physicians in our study using US as the standard demonstrates the adequate training of these professionals. Similar results have been reported in other studies that advocated the ability of family physicians to clinically diagnose goiter and thyroid gland enlargement.

The prevalence of thyroid nodules in our study was more than 40%, and US allowed assessment of the nodule size, location, number, pattern, margins, echogenicity, and acoustic transmission. Furthermore, other features were examined by the radiologist in cases in which lymph nodes were suspicious or reactive. Calcifications and vascularity were also assessed. These features were evaluated to categorize patients into most likely benign or most likely suspicious that need further evaluation by FNAB. Most of these features were reported by other various studies worldwide to evaluate thyroid nodules. Thyroid nodules are more likely to develop in women in the study. This is consistent with worldwide reports, as nodules are 9 times more common in women.

A family history of thyroid disease was a strong predictor of the development of thyroid nodules in our study. The presence of a first-degree relative with a thyroid malignancy increases the risk of thyroid cancer by up to 9-fold. The nature of the family history of either malignancy or otherwise needs to be clarified to stratify the risk, which is a limitation of the study. Thyroid nodules were more common in patients with iron deficiency anemia, which might be due to disease chronicity or severe illness, such as thyroid cancer. Other factors that can cause anemia, including heavy menstruation, should be controlled to obtain a clearer picture.

Table 5. Logistic Regression Models for Personal and Clinical Predictors Associated With Thyroiditis or Thyroid Nodule(s) Among Patients in the Family Medicine Center, Saudi Arabia (January 2020-December 2021) (N = 240).

| Factors associated with thyroiditis | B   | S.E. | Wald | df | Sig. | Adj OR | 95% C.I.for Adj OR |
|------------------------------------|-----|------|------|----|------|--------|--------------------|
| Enlarged gland (1 lobe or globally) | 1.708 | 0.404 | 17.889 | 1 | 0.000 | 5.519 | 2.501 - 12.180 |
| Family history of any thyroid disorder | 1.525 | 0.321 | 22.621 | 1 | 0.000 | 4.596 | 2.451 - 8.617 |
| Other autoimmune disease | 1.141 | 0.0395 | 8.346 | 1 | 0.004 | 3.130 | 1.443 - 6.789 |
| Vitamin D deficiency | .686 | 0.332 | 4.268 | 1 | 0.039 | 1.986 | 1.036 - 3.809 |
| Type 2 diabetes mellitus | .703 | 0.463 | 2.301 | 1 | 0.129 | 2.019 | 0.815 - 5.004 |
| Iron deficiency anemia | .223 | 0.506 | 0.195 | 1 | 0.659 | 1.250 | 0.464 - 3.373 |
| Female gender | .175 | 0.482 | 0.131 | 1 | 0.717 | 1.191 | 0.463 - 3.066 |
| Constant | −2.461 | 0.518 | 22.582 | 1 | 0.000 | 0.085 |

| Factors associated with thyroid nodule(s) | B   | S.E. | Wald | df | Sig. | Adj OR | 95% C.I.for Adj OR |
|------------------------------------------|-----|------|------|----|------|--------|--------------------|
| Iron deficiency anemia | 2.756 | 0.455 | 36.684 | 1 | 0.000 | 15.733 | 6.449 - 38.379 |
| Other autoimmune disease | 1.359 | 0.570 | 5.689 | 1 | 0.017 | 3.893 | 1.274 - 11.895 |
| Hypertension | 1.268 | 0.500 | 6.442 | 1 | 0.011 | 3.553 | 1.335 - 9.459 |
| Family history of any thyroid disorder | .737 | 0.357 | 4.267 | 1 | 0.039 | 2.090 | 1.038 - 4.207 |
| Vitamin D deficiency | .730 | 0.358 | 4.160 | 1 | 0.041 | 2.075 | 1.029 - 4.186 |
| Age 60+ years | 1.810 | 0.964 | 3.522 | 1 | 0.061 | 6.109 | 0.923 - 40.442 |
| Enlarged gland (1 lobe or globally) | .391 | 0.393 | 0.990 | 1 | 0.320 | 1.479 | 0.684 - 3.196 |
| Type 2 diabetes mellitus | .419 | 0.333 | 0.618 | 1 | 0.432 | 1.520 | 0.535 - 4.318 |
| Female gender | .368 | 0.506 | 0.530 | 1 | 0.467 | 1.445 | 0.536 - 3.895 |
| Constant | −2.469 | 0.514 | 23.056 | 1 | 0.000 | 0.085 |
To the best of our knowledge, this study is the first to determine the prevalence of thyroiditis and thyroid nodules according to clinical and laboratory findings at the primary health care level, all available literature reported these data at the secondary and tertiary levels of care. Using an electronic filing and record system to extract patient data minimized the risk of recall bias in this study.

This study has limitations. First, although the data from all patients who underwent thyroid US in our center were included in the analysis to minimize selection bias, the sample size was small.

Therefore, the analysis of imaging and laboratory data from a larger number of patients and corresponding demographic and family history characteristics is necessary to generalize the results to the Saudi population. Second, pregnant women were included in the study, and pregnancy can potentially influence thyroid gland function.

Conclusion

Thyroiditis and thyroid nodules were prevalent in our study. The presence of thyroid enlargement increased the risk of US-detected thyroiditis, and iron deficiency anemia and hypertension increased the risk of developing thyroid nodules. In addition, vitamin D deficiency, other autoimmune diseases, and a family history of thyroid disorders were associated with thyroiditis and thyroid nodules. This study raises family physicians’ awareness of the high prevalence of thyroiditis, thyroid nodules, and associated risk factors, increasing the suspicion of these entities, especially in patients with multiple risk factors. Further studies exploring other factors that were not investigated in this study are required. Moreover, patient perspectives on barriers to the use of FNAB should be assessed in future studies.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

This study was approved by the Institutional Review Board of Imam Abdulrahman Bin Faisal University (IRB number: IRB-2019-01-235).

ORCID iDs

Malak A. Al-Shammari https://orcid.org/0000-0002-7434-7432
Nouf A. AlShamlan https://orcid.org/0000-0002-8049-237X
Reem S. AlOmar https://orcid.org/0000-0003-4899-7965

References

1. Maniakas A, Davies L, Zafereo ME. Thyroid disease around the world. Otolaryngol Clin North Am. 2018;51(3):631-642. doi:10.1016/j.otc.2018.01.014
2. Awad SAS, Ashraf EM, Khaled AS, et al. The epidemiology of thyroid diseases in the Arab world: a systematic review. J Public Health Epidemiol. 2016;8(2):17-26. doi:10.5897/ jph2015.0713
3. Al-Dakheel MH, Haridi HK, Al-Bashir BM, et al. Prevalence of iodine deficiency disorders among school children in Saudi Arabia: results of a national iodine nutrition study. East Mediterr Health J. 2016;22(5):301-308.
4. Smith JJ, Chen X, Schneider DF, et al. Cancer after thyroidectomy: a multi-institutional experience with 1,523 patients. J Am Coll Surg. 2013;216(4):571-577. doi:10.1016/j.jamcollsurg.2012.12.022
5. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646-2655. doi:10.1056/nejmra021194
6. Dunn D, Turner C. Hypothyroidism in women. Nurs Womens Health. 2016;20(1):93-98. doi:10.1016/j.nwh.2015.12.002
7. Williams A, Bieler D, Wieler H, Williams D, Kaiser KP, Schwab R. Correlation between sonography and antibody activity in patients with Hashimoto thyroiditis. J Ultrasound Med. 2013;32(11):1979-1986. doi:10.7863/ultra.32.11.1979
8. Mariotti S, Caturegli P, Piccolo P, Barbessino G, Pinchera A. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab. 1990;71(3):661-669. doi:10.1210/jcem-71-3-661
9. Brito JP, Gionfriddo MR, Al Nofal A, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(4):1253-1263. doi:10.1210/jc.2013-2928
10. Vander JB, Gaston EA, Dawber TR. The significance of non-toxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968;69(3):537-540. doi:10.7326/0003-4819-69-3-537
11. Wettasinghe MC, Rosario S, Ratnautunga N, Wickramasinghe ND. Diagnostic accuracy of ultrasound characteristics in the identification of malignant thyroid nodules. BMC Res Notes. 2019;12(1):193. doi:10.1186/s13104-019-4235-y
12. Haugen BR, Sawka AM, Alexander EK, et al. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27(4):481-483. doi:10.1089/thy.2016.0628
13. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322. doi:10.1001/jamaoto.2014.1
14. Althubiti MA, Nour Eldein MM. Trends in the incidence and mortality of cancer in Saudi Arabia. Saudi Med J. 2018;39(12):1259-1262. doi:10.15537/smj.2018.12.23348
15. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028. doi:10.4158/ep12280.gl
16. Akbar DH, Ahmed MM, Al-Mughales I. Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics. *Acta Diabetol*. 2006;43(1):14-18. doi:10.1007/s0059200602048

17. Bennedbaek FN, Hegedüs L. The value of ultrasonography in the diagnosis and follow-up of subacute thyroiditis. *Thyroid*. 1997;7(1):45-50. doi:10.1089/thy.1997.7.45

18. Omori N, Omori K, Takano K. Association of the ultrasonographic findings of subacute thyroiditis with thyroid pain and laboratory findings. *Endocr J*. 2008;55(3):583-588. doi:10.1507/endocrj.k07e-163

19. Tokuda Y, Kasagi K, Iida Y, et al. Sonography of subacute thyroiditis: changes in the findings during the course of the disease. *J Clin Ultrasound*. 1990;18(1):21-26. doi:10.1002/jcu.1870180106

20. Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. *Isr Med Assoc J*. 2010;12(3):174-175.

21. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. *Exp Biol Med*. 2004;229(11):1136-1142. doi:10.1177/153537020422901108

22. Lin WY, Wan L, Tsai CH, Chen RH, Lee CC, Tsai FJ. Vitamin D receptor gene polymorphisms are associated with risk of Hashimoto’s thyroiditis in Chinese patients in Taiwan. *J Clin Lab Anal*. 2006;20(3):109-112. doi:10.1002/jcla.20110

23. Gordon CM, Feldman HA, Sinclair L, et al. Prevalence of vitamin D deficiency among healthy infants and toddlers. *Arch Pediatr Adolesc Med*. 2008;162(6):505. doi:10.1001/archpedi.162.6.505

24. Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. *Endocr Rev*. 1993;14(1):107-120. doi:10.1210/er.14.1.107

25. Zhao W, Han C, Shi X, et al. Prevalence of goiter and thyroid nodules before and after implementation of the universal salt iodization program in mainland China from 1985 to 2014: a systematic review and meta-analysis. *PLoS One*. 2014;9(10):e109549. doi:10.1371/journal.pone.0109549

26. Tigabu E, Bekele KB, Dachew BA. Prevalence of goiter and associated factors among schoolchildren in northeast Ethiopia. *Epidemiol Health*. 2017;39:e2017055. doi:10.4178/epih.e2017055

27. Bouq Y, Fazili FM, Gaffar HA. The current pattern of surgically treated thyroid diseases in the Medinah region of Saudi Arabia. *JK Pract*. 2006;13(1):9-14.

28. Park JY, Lee HJ, Jang HW, et al. A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. *Thyroid*. 2009;19(11):1257-1264. doi:10.1089/thy.2008.0021

29. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. *Thyroid*. 2017;27(11):1341-1346. doi:10.1089/thy.2017.0500

30. Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. *Am J Roentgenol*. 2002;178(3):687-691. doi:10.2214/ajr.178.3.1780687

31. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US features of thyroid malignancy: pearls and pitfalls. *Radiographics*. 2007;27(3):847-861. doi:10.1148/rg.273065038

32. Mazzaferri EL. Management of a solitary thyroid nodule. *N Engl J Med*. 1993;328(8):553-559. doi:10.1056/NEJM199302253280807

33. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. *J Natl Cancer Inst*. 1994;86(21):1600-1608. doi:10.1093/jnci/86.21.1600

34. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. *Thyroid*. 2006;16(2):181-186. doi:10.1089/thy.2006.16.181

35. Bremner AP, Feddema P, Joske DJ, et al. Significant association between thyroid hormones and erythrocyte indices in euthyroid subjects. *Clin Endocrinol*. 2012;76(2):304-311. doi:10.1111/j.1365-2265.2011.04228.x

36. Aktas G, Sit M, Karagoz I, et al. Could red cell distribution width be a marker of thyroid cancer? *J Coll Physicians Surg Pak*. 2017;27(9):556-558.

37. Yi KI, Ahn S, Park DY, et al. False-positive cytopathology results for papillary thyroid carcinoma: a trap for thyroid surgeons. *Clin Otolaryngol*. 2017;42(6):1153-1160. doi:10.1111/coa.12840